Sarepta Therapeutics, Inc. (SRPT) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights a mix of positive and negative factors. While there is a 16% revenue increase and promising product developments, significant cost of sales and operating losses are concerning. The Q&A reveals uncertainties in CEO succession and market dynamics, while management's unclear responses further cloud the outlook. The absence of market cap data limits prediction precision, but the neutral sentiment suggests a stock movement within -2% to 2%.
Key Financial Performance
Cash and Investments Exited 2025 with $954 million in cash and investments, growing $89 million in the fourth quarter.
Net Product Revenue for 2025 Totaled $1.86 billion, consisting of $966 million from PMO franchise and $899 million for ELEVIDYS.
Net Product Revenue for Q4 2025 PMOs totaled $259 million, relatively stable compared to Q4 2024. Individual PMO revenues: $148 million for EXONDYS 51, $34 million for VYONDYS 53, and $77 million for AMONDYS 45. ELEVIDYS revenue was $110 million, impacted by severe flu season and rescheduled infusions.
Total Revenues for 2025 $2.2 billion, an increase of 16% year-over-year. This includes $1.86 billion in net product revenue and $334 million in collaboration, contract manufacturing, and royalty revenue.
Cost of Sales for Q4 2025 $399 million, significantly increased due to a $193 million charge for excess inventory and purchase commitment cancellation fees.
Cost of Sales for 2025 Totaled $840 million, with nearly half reflecting failed production batches, inventory reserves, and other period charges.
Non-GAAP Expenses for 2025 Totaled $1.85 billion, with $884 million related to the Arrowhead collaboration. Core operating expenses (excluding Arrowhead) were $965 million.
Operating Loss for 2025 GAAP operating loss of $700 million and non-GAAP operating loss of $492 million. Adjusting for restructuring and Arrowhead expenses, underlying business delivered $226 million GAAP operating profit and $391 million non-GAAP operating profit.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ELEVIDYS: ELEVIDYS has been approved for all ambulatory patients aged four and over, with a sirolimus pretreatment study underway for non-ambulatory patients. Over 1,200 patients have been treated, and the therapy shows significant disease-modifying benefits. Educational initiatives are being launched to address information deficits and improve understanding of its benefits.
PMO Therapies: The three approved PMO therapies (EXONDYS 51, VYONDYS 53, and AMONDYS 45) have shown stability in the market. ESSENCE confirmatory study results support transitioning AMONDYS and VYONDYS to traditional approval. These therapies have over 90% compliance rates and a strong safety profile.
siRNA Pipeline: The siRNA pipeline includes five clinical-stage programs targeting neuromuscular, pulmonary, and CNS diseases. Programs for DM1 and FSHD are progressing, with preliminary data expected soon. A Huntington's disease program has also been initiated.
ELEVIDYS Market Expansion: ELEVIDYS has launched in Japan, with a $40 million milestone payment expected from Roche. Educational efforts are being expanded to address treatment hesitancy and improve adoption among patients and physicians.
Financial Position: Sarepta ended 2025 with $954 million in cash and investments, achieving positive operating cash flow. Revenue guidance for 2026 is $1.2 billion to $1.4 billion, with improved gross margins expected.
Cost Management: Cost reduction measures have been implemented, with 2026 non-GAAP expenses projected at $800 million to $900 million. Inventory adjustments and lower production volumes are expected to improve margins.
Leadership Transition: CEO Doug Ingram announced plans to retire by the end of 2026, citing family commitments and a personal connection to muscular dystrophy. A search for his successor is underway.
Pipeline Focus: Sarepta is focusing on advancing its siRNA pipeline and addressing unmet needs in rare diseases, including DM1, FSHD, and Huntington's disease.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
ELEVIDYS Safety Concerns: The safety events of 2025, including tragic incidents, reshaped perceptions of gene therapy and ELEVIDYS specifically. This has created hesitancy among patients and physicians, impacting demand and requiring significant educational efforts to address information deficits.
Delayed Commercial Impact of ELEVIDYS Initiatives: The long cycle time for ELEVIDYS treatments and the timing of educational initiatives mean that the impact on demand may not be seen until the second half of 2026, potentially affecting near-term sales.
Inventory and Production Challenges: A review of raw material inventory led to a $193 million charge for excess inventory and purchase commitment cancellations. This reflects challenges in aligning production with demand and avoiding waste.
Regulatory and Approval Risks: The company is awaiting FDA decisions on transitioning AMONDYS and VYONDYS to traditional approval and on the pathway for resuming ELEVIDYS treatment in non-ambulatory patients. These regulatory uncertainties could impact future operations and revenue.
Market Hesitancy and Information Deficit: There is an information imbalance regarding the benefits and risks of ELEVIDYS, leading to treatment hesitancy among patients and physicians. This requires extensive educational efforts to rebuild confidence.
Economic and Financial Pressures: Despite a strong financial position, the company faces pressures from high costs, including a $200 million milestone payment to Arrowhead and significant R&D and SG&A expenses. These costs could strain profitability if revenue growth does not meet expectations.
Pipeline and Development Risks: The success of the siRNA pipeline and other programs is critical for future growth, but these programs are still in early stages and carry inherent risks of failure or delays.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: Sarepta expects total net product revenue for 2026 to be in the range of $1.2 billion to $1.4 billion for its approved therapies. The company advises modeling towards the low end of the range due to the timing of educational initiatives and long cycle times for ELEVIDYS.
ELEVIDYS Revenue Expectations: ELEVIDYS revenue is expected to be influenced by educational efforts to address information deficits. Near-term sales may be impacted, but the ultimate opportunity remains significant. The company anticipates seeing the impact of these efforts well into the second half of 2026.
ELEVIDYS Market Opportunity: The majority of Duchenne patients remain untreated, presenting a significant opportunity. Sarepta plans to address information deficits to ensure patients and physicians are informed about ELEVIDYS' benefits.
ELEVIDYS Non-Ambulatory Patient Study: A sirolimus pretreatment study for non-ambulatory patients is underway, with results expected by the end of 2026. Positive results could lead to discussions with the FDA for resuming commercial dosing in this population.
ELEVIDYS Long-Term Data: Three-year EMBARK data shows significant and durable efficacy, with a 73% slowing of disease progression in time to rise and a 70% slowing in the 10-meter walk run. This data supports ELEVIDYS as a disease-modifying therapy.
Pipeline Advancements: Sarepta is advancing its siRNA pipeline with five clinical-stage programs targeting neuromuscular, pulmonary, and CNS diseases. Preliminary data for DM1 and FSHD programs is expected by the end of Q1 2026.
Financial Position: Sarepta expects to be cash flow positive and profitable on a non-GAAP basis in 2026, supported by a strong cash balance and disciplined financial execution.
Gross Margin Expectations: Margins are expected to improve in 2026, with unit volume margins in the high 70% range.
Collaboration Revenue: Sarepta anticipates $450 million to $550 million in collaboration, contract manufacturing, and royalty revenues in 2026, including a $40 million milestone payment from Roche.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How does the Board view internal versus external candidates for the CEO position?
A:The Board is considering both internal and external candidates seriously. They aim to choose someone who understands the challenges, can execute plans, lead the team, and shares the company's cultural values. The CEO emphasized the importance of continuity and the exceptional team at the company.
Q:What are the key metrics for evaluating the success of ELEVIDYS in the first half of the year?
A:Key metrics include enrollment forms, infusions, regional advisory boards, and market research. These metrics will help assess whether people are embracing and understanding the data on the therapy.
Q:What benchmarks should be considered for siRNA readouts in 1Q?
A:The focus should be on safety and muscle concentration. Preclinical data suggest that the therapy can achieve greater muscle concentration safely, which is critical for knockdown and downstream splicing.
Q:When will Sarepta be ready to start pivotal studies for DM1 and FSHD?
A:The company is working towards Phase III studies, informed by the MAD study and manufacturing readiness. The timing for accelerated approval will depend on the state of the environment and other companies' approvals.
Q:How are clinicians currently risk stratifying patients for ELEVIDYS?
A:Clinicians consider factors like liver enzymes, age, weight, steroid exposure, and concomitant medications. Some physicians lean towards younger patients, and about 25% of sites are using sirolimus proactively.
Q:What is the size of the Japanese market for ELEVIDYS, and what is the potential for non-ambulatory patient treatment?
A:The Japanese market is significant due to its advanced healthcare system and large population. Roche is leading the launch in Japan. The potential for non-ambulatory patient treatment would require additional activities and approvals.
Q:What are the quarterly dynamics and guidance for ELEVIDYS?
A:Quarterly dynamics can be noisy due to the rare disease nature and high cost per patient. Guidance for 1Q is flat to 15% down, with a full-year range of $1.2 billion to $1.4 billion. Educational efforts and enrollment-to-infusion time will impact revenue, with significant acceleration expected in the second half of the year.
Q:What PD data should be anticipated for DM1 and FSHD in the upcoming readouts?
A:For DM1, early DMPK knockdown data will be shared. For FSHD, DUX4 target gene correction data will be provided. Splicing data for DM1 will be available in the second half of the year.
Q:What is the status of the ENDEAVOR Cohort 8 trial?
A:There is significant interest in Cohort 8, with screening ongoing. Dosing is expected soon, and data will be presented by the end of the year.
Q:What is the impact of DMD being added to the federal recommended uniform screening panel?
A:This is a significant development, but the impact will take time as states roll out the recommendation. ELEVIDYS is currently approved for boys aged four years and older, so lowering the age range will be necessary to fully benefit from newborn screening.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers or lacked clarity on the following: 1. Specific size and ordering dynamics of the Japanese market for ELEVIDYS, deferring to Roche for details. 2. Exact timing and benchmarks for pivotal studies for DM1 and FSHD, stating it depends on various factors. 3. Details on the impact of PMO competition and dual use with ELEVIDYS, providing only general observations. 4. Specific enrollment numbers for ENDEAVOR Cohort 8, stating only that screening is ongoing. 5. Precise timing for state-level implementation of DMD newborn screening and its immediate impact on ELEVIDYS demand.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AMONDYS
Ambulatory Assessment
Chief Commercial
Cohort
Cohorts
Commercial Officer
EMBARK
Moss
Phase III
Roche
SCA
Technical Difficulty
Wong
body
caregiver
charge
closing
control group
cycle
debt
decision
disease benefit
disease progression
evidence ELEVIDYS
information deficit
inventory
material
messaging
meter walk
muscle MRI
patient ELEVIDYS
physician
pillar
place
profile
sirolimus
timing
value
world evidence
SRPT Transcript
Sarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-8
Sarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call summary highlights a 20% YoY revenue growth and a shift from a net loss to a $50 million net income, indicating strong financial performance. The increase in R&D expenses supports future growth, while improved cash flow reflects efficient management. Despite the lack of strategic and operational updates, the financial results and positive market demand for new therapies suggest a strong positive sentiment. The absence of negative feedback in the Q&A further supports this outlook.
Sarepta Therapeutics, Inc. (SRPT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-3
Sarepta Therapeutics, Inc. (SRPT) Q4 2025 Earnings Call Transcript
Unknown2-25
The earnings call highlights a mix of positive and negative factors. While there is a 16% revenue increase and promising product developments, significant cost of sales and operating losses are concerning. The Q&A reveals uncertainties in CEO succession and market dynamics, while management's unclear responses further cloud the outlook. The absence of market cap data limits prediction precision, but the neutral sentiment suggests a stock movement within -2% to 2%.
SRPT Slides
SRPT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
